How should symptomatic obstructive hypertrophic cardiomyopathy be managed?

Management of Symptomatic Obstructive Hypertrophic Cardiomyopathy

For patients with symptomatic obstructive HCM, start with beta-blockers or non-dihydropyridine calcium channel blockers as first-line therapy; if symptoms persist despite these agents, add a cardiac myosin inhibitor (mavacamten in adults), disopyramide (with AV nodal blockade), or proceed to septal reduction therapy at an experienced center. 1

Stepwise Treatment Algorithm

First-Line Pharmacotherapy

• Beta-blockers (e.g., metoprolol, propranolol) or non-dihydropyridine calcium channel blockers (verapamil, diltiazem) are the initial medications of choice
• These agents reduce heart rate, increase diastolic filling time, and decrease myocardial contractility
• Titrate to maximum tolerated doses before declaring treatment failure

Second-Line Options for Persistent Symptoms

When patients remain symptomatic on first-line therapy, three Class 1 recommendations exist 1:

Option 1: Cardiac Myosin Inhibitors (Adults Only)

• Mavacamten is the FDA-approved agent that directly targets sarcomeric hypercontractility
• Provides substantial LVOT gradient reduction and improves exercise capacity, NYHA class, and quality of life 2, 3
• Recent evidence suggests myosin inhibitors may be superior to beta-blockers as monotherapy, with the MAPLE-HCM trial showing aficamten outperformed metoprolol in peak oxygen uptake and functional status 2
• Critical caveat: Discontinue immediately if LVEF drops below 50% 1
• Absolute contraindication in pregnancy due to teratogenic effects 1

Option 2: Disopyramide

• Must be combined with an AV nodal blocking agent (beta-blocker or calcium channel blocker) to prevent rapid ventricular response
• Provides additional negative inotropic effect
• Anticholinergic side effects (dry mouth, urinary retention, constipation) limit tolerability in some patients

Option 3: Septal Reduction Therapy (SRT)

• Reserved for patients with drug-refractory symptoms or severe obstruction
• Must be performed at experienced HCM centers - outcomes are significantly better at comprehensive centers 1

Septal Reduction Therapy Selection

Surgical Septal Myectomy

• Gold standard with lower residual gradients (<10 mmHg), lower re-intervention rates, and superior long-term survival compared to alcohol septal ablation 4, 5
• Preferred when:
  • Intrinsic mitral valve disease present
  • Papillary muscle abnormalities exist
  • Markedly thickened septum (>30 mm)
  • Multiple levels of obstruction
  • Long mid-cavity obstruction
  • No suitable septal perforator artery 4
• Requires intraoperative TEE to assess mitral valve anatomy and adequacy of myectomy 1

Alcohol Septal Ablation

• Less invasive alternative for high-risk surgical candidates
• Higher residual gradients (15-20 mmHg), re-intervention rates (10-20%), and permanent pacemaker requirement (10-17%) 5
• Requires TTE or TEE with contrast injection to identify appropriate septal perforator 1
• Important limitation: Incomplete tissue necrosis leads to greater long-term mortality risk beyond 5 years 5

Post-Procedure Monitoring

• TTE within 3-6 months after any SRT to evaluate results 1

Common Pitfalls to Avoid

1. Premature escalation: Ensure first-line agents are maximally titrated before adding second-line therapy
2. Myosin inhibitor misuse: Do not use in pregnancy, and monitor LVEF closely - discontinue if <50%
3. Disopyramide monotherapy: Always combine with AV nodal blocking agent
4. Performing SRT at low-volume centers: Outcomes are operator and center-dependent; refer to experienced HCM centers 1
5. Ignoring concomitant mitral pathology: Surgical myectomy allows correction of complex mitral abnormalities that alcohol ablation cannot address 4, 5

Emerging Paradigm Shift

The introduction of cardiac myosin inhibitors represents a fundamental change from symptomatic management to disease modification 2, 3. Evidence suggests these agents may eventually become first-line therapy, though long-term safety data and optimal patient selection criteria require further study. Current guidelines position them as second-line after traditional agents, but this may evolve as more data accumulates.